Compare Viatris Inc (VTRS) vs Clear Secure Inc (YOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs Clear Secure Inc — how do they compare? Viatris Inc trades at $17.49 (market cap $20.03B), while Clear Secure Inc trades at $43.54 (market cap $4.44B). The key difference: Viatris Inc is far larger — about 4.5× Clear Secure Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Viatris Inc for 57 Days and Clear Secure Inc for 19 Days on average.
| VTRS | YOU | |
|---|---|---|
Market Cap | $20.03B | $4.44B |
Volume | 14,109,977 | 1,477,828 |
Sector | Health | Technology |
52-Week High | $18.27 | $62.36 |
52-Week Low | $9.74 | $29.61 |
Typical Hold Time | 57 Days | 19 Days |
Enterprise Value | $32.15B | $3.59B |
Dividend Yield | 2.75% | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.
Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.
Clear Secure (YOU) trades at $42.58, up 2.6% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with 27% revenue growth in Q2 2026, beating earnings estimates, and robust profitability metrics including 66.7% gross margin and 90.3% ROE. Recent partnership with CrowdStrike and corporate membership launch highlight growth initiatives.
The stock offers 44% upside to the $61.40 consensus target with analyst sentiment divided equally between Buy and Hold. Key risks include competitive pressures and execution of expansion plans. Strong cash flow generation and accelerating membership growth support the bullish case, though valuation multiples remain elevated.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
